Efficacy News and Research

RSS
Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Cardium second-quarter net loss decreases to $0.7 million

Cardium second-quarter net loss decreases to $0.7 million

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Repros Therapeutics second-quarter net loss decreases to $1.3 million

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Lentigen receives NIH SBIR grant for program on clinical vector for TCR immunotherapy targeted to melanoma

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis second-quarter pro forma net operating loss increases to $15.5 million

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Morphine plus oxycodone IV combination exhibits improved analgesia, tolerability compared to IV morphine

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

Fibrocell Science submits clinical study report to FDA for azficel-T Phase II/III trial for acne scars

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

FDA accepts Salix's XIFAXAN550 sNDA for Priority Review

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Scientists induce nerve tissue regeneration in patients with spinal cord injury

Ironwood provides investor update for second-quarter 2010

Ironwood provides investor update for second-quarter 2010

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Sucampo Pharmaceuticals second-quarter 2010 total revenue declines to $13.8 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

Ardea Biosciences second-quarter total revenues decline to $3.5 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

BioSpecifics Technologies second-quarter total revenues decrease to $0.9 million

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

Study generates promising data about sustained durability of Zyclara's efficacy versus cryosurgery alone

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

NeurogesX net loss for second-quarter 2010 increases to $10.2 million

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Clinical trials in Asia, Africa confirm safety, effectiveness of rotavirus vaccine

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

Medtronic completes enrollment in Complete SE vascular stent superficial femoral artery clinical study

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

Progenics announces EMA CHMP positive opinion for RELISTOR in pre-filled syringes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.